<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929523</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0034</org_study_id>
    <secondary_id>2019-A00546-51</secondary_id>
    <nct_id>NCT03929523</nct_id>
  </id_info>
  <brief_title>Hypothermic Oxygenated Perfusion for Extended Criteria Donors in Liver Transplantation (HOPExt)</brief_title>
  <acronym>HOPExt</acronym>
  <official_title>End-ischemic Hypothermic Oxygenated Perfusion for Extended Criteria Donors in Liver Transplantation - A Multicenter, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the scarce donor supply, an increasing number of so-called marginal or extended
      criteria donor (ECD) organs have been used for liver transplantation. These ECD liver grafts
      are, however, known to be associated with a higher rate of early allograft dysfunction (EAD)
      and primary non-function because of a greater vulnerability to ischemia-reperfusion injury.
      The end-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE) technique may improve
      outcomes of liver transplantation with ECD grafts by decreasing reperfusion injury.

      The study aim is to assess the efficacy of HOPE used before transplantation of ECD liver
      grafts from brain-dead donors in reducing postoperative EAD within the first 7 postoperative
      days (POD) compared to simple cold static storage.

      The study is comparative open-label, multicenter, national, prospective, randomized, in two
      parallel groups, using the gold standard procedure as control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentric randomized controlled trial concerns adult patients undergoing whole liver
      transplantation in any of the 8 participating centers in France, who will receive an ECD
      liver graft from a brain-dead donor.

      After providing written informed consent prior to the performance of any study specific
      procedure, the recruited patients will be randomized either in the experimental group (HOPE
      group) or in the control group.

      In the HOPE group, ECD liver grafts will undergo a hypothermic oxygenated perfusion (HOPE)
      via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the &quot;back-table&quot;
      phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified
      Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion
      Solution (Belzer-MPS, CE-certified).

      The control group will consist of a classic static cold (4°C) storage with Institute George
      Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold
      standard procedure in liver transplantation.

      The primary endpoint will be early allograft dysfunction (EAD) according to Olthoff's
      criteria, which will be compared with the Model of Early Allograft Function score (MEAF
      score) and the Liver Graft Assessment Following Transplantation risk factor (L-GrAFT).

      According to the primary endpoint, a sample size of 133 patients per randomized group (266 in
      total) is needed. The duration of the inclusion period is expected to be 24 months with a
      1-year follow-up for each patient.

      The potential impacts of the study are expected on 3 levels: (1) for the patient, decreased
      postoperative morbidity and mortality of liver transplantation with ECD donors; (2) for the
      French liver transplantation community, familiarization with liver machine perfusion, and (3)
      economically, decreased costs of liver transplantation (health economic analysis included in
      the study).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early allograft dysfunction (EAD) according to Olthoff criteria.</measure>
    <time_frame>During the first postoperative week</time_frame>
    <description>EAD is defined by the presence of at least one of the following criteria:
Bilirubin level &gt; 10 mg/dL (i.e. 171 µmol/L) on POD 7
International Normalized Ratio (INR) &gt; 1.6 on POD 7
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels &gt; 2000 IU/L within the first 7 PODs Additionally EAD will be also assessed by the MEAF score and the L-GrAFT risk factor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Model of Early Allograft Function score (MEAF score).</measure>
    <time_frame>During the first 3 postoperative days.</time_frame>
    <description>The MEAF score includes bilirubin, ALT max and INR max at postperative day 3. Range 0 (better outcome) to 10 (worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Graft Assessment Following Transplantation risk factor (L-GrAFT)</measure>
    <time_frame>During the first 10 postoperative days.</time_frame>
    <description>L-GrAFT includes aspartate aminotransferase (AST), INR, total bilirubin and platelets every day until postoperative day 10. Range -6 (better outcome) to +6 (worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Untargeted liver graft metabolic profiling</measure>
    <time_frame>Day of liver transplantation (Day 0)</time_frame>
    <description>Untargeted liver graft metabolic profiling (by High-Resolution Nuclear Magnetic Resonance - 1H HR-Nuclear Magnetic Resonance (NMR) Spectrometer) on liver graft biopsies on the back-table before and after liver machine perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of post-reperfusion syndrome</measure>
    <time_frame>Day of liver transplantation (Day 0)</time_frame>
    <description>Defined as a 50% decrease in median arterial pressure during the 5 minutes following the graft revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day morbidity and mortality</measure>
    <time_frame>During the first 90 days after surgery.</time_frame>
    <description>Severe postoperative complications (Dindo-Clavien ≥3) / death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intermediate care unit stay (days)</measure>
    <time_frame>From randomization until intermediate care unit discharge, estimated up to 7 days</time_frame>
    <description>Duration of intermediate care unit stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (days)</measure>
    <time_frame>From randomization until hospital discharge, estimated up to 21 days</time_frame>
    <description>Duration of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver contrast-enhanced MRI including a Magnetic Resonance CholangioPancreatography (MRCP)</measure>
    <time_frame>Within 1 year after liver transplantation</time_frame>
    <description>Assessment of intra- and extrahepatic biliary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-month and one-year patient and graft survivals</measure>
    <time_frame>within one year after liver transplantation</time_frame>
    <description>Actuarial graft and patient's survival rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital costs (Euros) of liver transplantation</measure>
    <time_frame>At one year after liver transplantation</time_frame>
    <description>Hospital costs of liver transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>HOPE group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypothermic oxygenated perfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>classic static cold storage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)</intervention_name>
    <description>In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the &quot;back-table&quot; phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified).</description>
    <arm_group_label>HOPE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>classic static cold storage</intervention_name>
    <description>The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent prior to the performance of any study specific
             procedure

          -  Affiliated to the French social security system

          -  Recipient age ≥ 18 years

          -  Patients undergoing primary liver transplantation.

          -  Candidate for a first elective liver transplantation, whatever the indication, with a
             liver graft harvested from a brain-dead ECD defined by the presence of at least one of
             the following criteria:

               -  Donor age &gt; 65 years

               -  Intensive care unit stay &gt; 7 days

               -  BMI &gt; 30

               -  Proven macro-steatosis biopsy ≥ 30%

               -  Natremia &gt; 155 mmol/L at any time

               -  AST &gt; 150 IU/mL at any time

               -  ALT &gt; 170 IU/mL at any time.

        Exclusion Criteria:

          -  Fulminant hepatic failure

          -  Retransplantation

          -  Split liver transplantation

          -  Living donor liver transplantation

          -  Grafts donated after cardiac arrest (DCD grafts)

          -  Domino transplantation

          -  Combined liver transplant

          -  Unexpected medical contraindication to liver transplantation

          -  Patient participating in other interventional research, excluding routine care
             research (old regulation) and category 2 research not interfering with primary
             endpoint analysis

          -  Patient under legal protection

          -  Patient deprived of liberty by a judicial or administrative decision

          -  Patient refusing to participate in the study

          -  Pregnant or lactating women

          -  Inability to understand information concerning the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mickael LESURTEL</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mickael LESURTEL</last_name>
    <phone>+33 4 72 07 11 00</phone>
    <email>mickael.lesurtel@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahé RAFFIN</last_name>
    <phone>+33 4 26 73 27 38</phone>
    <email>mahe.raffin@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of HPB surgery and liver transplantation Beaujon University Hospital</name>
      <address>
        <city>Clichy</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier SOUBRANE</last_name>
      <phone>+33 1 40 87 50 00</phone>
      <email>olivier.soubrane@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes - Department of HPB surgery and liver transplantation</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mircea CHIRICA</last_name>
      <phone>+33 4 76 76 75 75</phone>
      <email>mchirica@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Mircea CHIRICA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès BONADONA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of HPB surgery and liver transplantation Claude Huriez University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BOLESLAWSKI</last_name>
      <phone>+33 3 20 44 42 60</phone>
      <email>emmanuel.boleslawski@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickaël LESURTEL</last_name>
      <phone>+33 4 72 07 11 00</phone>
      <email>mickael.lesurtel@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mahé RAFFIN</last_name>
      <phone>+33 4 26 73 27 38</phone>
      <email>mahe.raffin@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>APHP - Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier SCATTON</last_name>
      <email>olivier.scatton@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier SCATTON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of HPB surgery and liver transplantation Pontchaillou University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel RAYAR</last_name>
      <email>michel.rayar@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre - Department of HPB surgery and liver transplantation</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BACHELLIER</last_name>
      <email>philippe.bachellier@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of HPB surgery and liver transplantation Paul Brousse University Hospital</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René ADAM</last_name>
      <phone>+33 1 45 59 30 49</phone>
      <email>rene.adam@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010 Aug;16(8):943-9. doi: 10.1002/lt.22091.</citation>
    <PMID>20677285</PMID>
  </reference>
  <reference>
    <citation>Pareja E, Cortes M, Hervás D, Mir J, Valdivieso A, Castell JV, Lahoz A. A score model for the continuous grading of early allograft dysfunction severity. Liver Transpl. 2015 Jan;21(1):38-46. doi: 10.1002/lt.23990. Epub 2014 Nov 24.</citation>
    <PMID>25204890</PMID>
  </reference>
  <reference>
    <citation>Agopian VG, Harlander-Locke MP, Markovic D, Dumronggittigule W, Xia V, Kaldas FM, Zarrinpar A, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg. 2018 May 1;153(5):436-444. doi: 10.1001/jamasurg.2017.5040. Erratum in: JAMA Surg. 2018 May 1;153(5):498.</citation>
    <PMID>29261831</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>Liver machine perfusion</keyword>
  <keyword>extended criteria donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

